BIOMAT Database Logo BIOMAT Database Logo

Thymomas and thymic carcinomas: prognostic factors and multimodal management. 2014

Bernhard Moser, and Margit Scharitzer, and Stefan Hacker, and Jan Ankersmit, and Jose Ramon Matilla, and Georg Lang, and Clemens Aigner, and Shahrokh Taghavi, and Walter Klepetko
Medical University of Vienna-Thoracic Surgery Wien, Wien, Austria.

BACKGROUND Thymomas and thymic carcinomas are rare malignant tumors. We report the experience with the resection and multimodal treatment at a single department in Central Europe in the years 2001 to 2010. OBJECTIVE We sought to determine prognostic factors in this patient population. METHODS A 10-year retrospective analysis of 84 resections on 72 patients for thymomas/thymic carcinomas or their recurrences was performed. RESULTS Patients admitted to a single thoracic surgery center presented with Masaoka-Koga stage I (29.2%), II (43.1%), III (13.9%), and IV (13.9%). In approximately 88.9% of cases, a complete resection could be reached. Using overall survival as an outcome measure, the 5-year survival rate was 87%. Of all the cases presented, 9.7% cases showed tumor recurrence and 6.9% cases showed tumor progression. There was decreased survival rate with increasing Masaoka-Koga stage (p = 0.017) and incomplete resection (p < 0.001). CONCLUSIONS Completeness of resection and Masaoka-Koga stage were significant prognostic factors. Multidisciplinary treatments of patients with thymoma or thymic carcinoma result in good patient care, and global efforts with larger number of patients are needed to elucidate more about the biology, diagnosis, and treatment of these tumors.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Bernhard Moser, and Margit Scharitzer, and Stefan Hacker, and Jan Ankersmit, and Jose Ramon Matilla, and Georg Lang, and Clemens Aigner, and Shahrokh Taghavi, and Walter Klepetko
[Management of thymomas and thymic carcinomas].
January 2020, Ugeskrift for laeger,
Bernhard Moser, and Margit Scharitzer, and Stefan Hacker, and Jan Ankersmit, and Jose Ramon Matilla, and Georg Lang, and Clemens Aigner, and Shahrokh Taghavi, and Walter Klepetko
Thymomas and thymic carcinomas.
November 1990, Seminars in diagnostic pathology,
Bernhard Moser, and Margit Scharitzer, and Stefan Hacker, and Jan Ankersmit, and Jose Ramon Matilla, and Georg Lang, and Clemens Aigner, and Shahrokh Taghavi, and Walter Klepetko
[Thymomas and thymic carcinomas].
December 2010, Revue des maladies respiratoires,
Bernhard Moser, and Margit Scharitzer, and Stefan Hacker, and Jan Ankersmit, and Jose Ramon Matilla, and Georg Lang, and Clemens Aigner, and Shahrokh Taghavi, and Walter Klepetko
Prognostic value of DNA flow cytometry in thymomas and thymic carcinomas.
June 1990, Southern medical journal,
Bernhard Moser, and Margit Scharitzer, and Stefan Hacker, and Jan Ankersmit, and Jose Ramon Matilla, and Georg Lang, and Clemens Aigner, and Shahrokh Taghavi, and Walter Klepetko
Chemotherapy of thymomas and thymic carcinomas.
May 2001, Chest surgery clinics of North America,
Bernhard Moser, and Margit Scharitzer, and Stefan Hacker, and Jan Ankersmit, and Jose Ramon Matilla, and Georg Lang, and Clemens Aigner, and Shahrokh Taghavi, and Walter Klepetko
Therapeutic options in thymomas and thymic carcinomas.
April 2022, Expert review of anticancer therapy,
Bernhard Moser, and Margit Scharitzer, and Stefan Hacker, and Jan Ankersmit, and Jose Ramon Matilla, and Georg Lang, and Clemens Aigner, and Shahrokh Taghavi, and Walter Klepetko
COX-2 upregulation in thymomas and thymic carcinomas.
November 2006, International journal of cancer,
Bernhard Moser, and Margit Scharitzer, and Stefan Hacker, and Jan Ankersmit, and Jose Ramon Matilla, and Georg Lang, and Clemens Aigner, and Shahrokh Taghavi, and Walter Klepetko
Steroid receptor expression in thymomas and thymic carcinomas.
October 2011, Cancer,
Bernhard Moser, and Margit Scharitzer, and Stefan Hacker, and Jan Ankersmit, and Jose Ramon Matilla, and Georg Lang, and Clemens Aigner, and Shahrokh Taghavi, and Walter Klepetko
Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology.
May 2013, Journal of the National Comprehensive Cancer Network : JNCCN,
Bernhard Moser, and Margit Scharitzer, and Stefan Hacker, and Jan Ankersmit, and Jose Ramon Matilla, and Georg Lang, and Clemens Aigner, and Shahrokh Taghavi, and Walter Klepetko
Aberrant methylation: common in thymic carcinomas, rare in thymomas.
December 2005, Oncology reports,
Copied contents to your clipboard!